Sign in
Taking people in United StatesNo phase

Tests low-dose liver radiation with immunotherapy in lung cancer or melanoma

Tests low-dose liver radiation added to immunotherapy in adults with liver-spread lung cancer or melanoma.

Key facts

Who runs it
Jordan Kharofa
Where
Cincinnati, United StatesSee the site
Trial code
Registry title
Promoting Immunotherapy Efficacy With Low-Dose Liver RT
Status
Recruiting
People taking part
21 people, planned
Started
15 Dec 2025
Expected to end
15 Dec 2029
Type of study
Interventional
Treatments tested
  • LD-LRT
Record updated
27 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with melanoma or non-small cell lung cancer that has spread to the liver and who are getting PD-1 or PD-L1 immunotherapy. It tests adding low-dose liver radiation.

Age
18 years or older.
Sex
All sexes can join.
Disease stage
Biopsy-proven non-small cell lung cancer or melanoma, with liver metastases seen on imaging. ECOG performance status 2 or lower (or Karnofsky 60% or higher).
Earlier treatment
Must be planning to have standard-care PD-L1 or PD-1 checkpoint immunotherapy during the radiation. Adjuvant immunotherapy within 6 months of enrollment excludes a person.
Biomarker or test result
For NSCLC in cohort 1, the driver mutations EGFR, ALK, ROS1 or RET are not allowed.

Main reasons for not taking part

  • Adjuvant immunotherapy within 6 months of enrollment
  • NSCLC with EGFR, ALK, ROS1 or RET mutation (cohort 1)
  • Uncontrolled other illness that makes taking part unreasonably hazardous
  • Other cancer that could interfere with the safety or results
  • Pregnancy

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Age ≥18 years
  • ECOG performance status ≤2 (or Karnofsky ≥60%, see Appendix A)
  • Patients must have adequate organ and marrow function to receive standard of care immunotherapy and/or chemoimmunotherapy as per the treating medical oncologist
  • Must be planning to, and able to, undergo active treatment with PD-L1 or PD-1 checkpoint immunotherapy given per standard care throughout the duration of the RT intervention per their treating physician; Note: Patients may receive other SOC CTLA 4 inhibitors or other SOC chemotherapy/immunotherapy in combination with a SOC PD-L1 or PD-1 checkpoint inhibitor and remain eligible
  • Biopsy proven Non-Small Cell Lung Cancer (NSCLC) or Melanoma
  • Radiographic evidence of liver metastases
  • Women of child-bearing potential and men must agree to use adequate contraception (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation
  • Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants
  • Patients must have insurance authorization to proceed with radiotherapy prior to initiation of radiation treatment on study

Who cannot take part

  • Patients with prior immunotherapy use in the adjuvant setting for NSCLC or Melanoma are eligible unless the adjuvant immunotherapy was delivered within 6 months of enrollment
  • Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen in the opinion of the Investigator
  • Pregnant women are excluded from this study considering the use of ionizing radiation
  • Patients with uncontrolled intercurrent illness or any other significant condition(s) that would make participation in this protocol unreasonably hazardous, in the opinion of the Investigator
  • Patients with NSCLC are ineligible for enrollment in cohort 1 if the presence of the following driver mutations are noted: EGFR, ALK, ROS1, RET

Where in United States

  • University of Cincinnati Medical CenterCincinnati, United StatesContact: UCCC CTOTaking people

About the trial

What the trial wants to find out

The purpose of this study is to see if adding Low-Dose Liver Radiation (LD-LRT) improves progression free survival (PFS). This study is for patients with either melanoma or non-small cell lung cancer (NSCLC), with liver metastases, and receiving immunotherapy.

The group in the trial

  • LD-LRTTreatment being tested

    Low-dose radiation to the liver the week prior to Cycles 1, 2 and 3 of systemic treatment.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
PRIME-LRT: PRomoting IMmunotherapy Efficacy With Low-Dose Liver RT
Plain-language title
Tests low-dose liver radiation with immunotherapy in lung cancer or melanomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
27 February 2026